<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218514</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-17-07</org_study_id>
    <nct_id>NCT03218514</nct_id>
  </id_info>
  <brief_title>Venous Thromboprophylaxis in Bariatric Surgery</brief_title>
  <official_title>Evaluating Body Size Descriptors on Peak Anti-Xa Levels in Bariatric Surgery Obese Patients Receiving Low Molecular Weight Heparin Fixed Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to compare the influence of total body-weight (TBW), lean
      body-weight (LBW), ideal body-weight (IBW) or Body Mass Index (BMI) on peak anti-Xa levels at
      steady-state in bariatric surgery (BS) morbidly obese patients receiving a fixed double dose
      of dalteparin (5000 IU subcutaneously, twice daily a day) for venous thromboembolism (VTE)
      prevention. Secondary aims of this study are to identify which body size descriptors (BSD)
      has the greatest impact and could further be explored for an adjusted low molecular weight
      heparin (LMWH) dosing algorithm for achieving optimal VTE prevention in BS severely obese
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severely obese patients undergoing bariatric surgery (BS) are at increased risk for venous
      thromboembolism (VTE). How standard LMWH regimen should be adapted to provide both sufficient
      efficacy and safety in this setting is unclear. The aim of this study is to compare the
      influence of four BSD on peak anti-Xa levels in BS obese patients receiving high LMWH fixed
      doses to identify which one had the greatest impact and could further be proposed in
      LMWH-based thromboprophylaxis dosing algorithms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients whose peak plasma anti-Xa levels is in the prophylactic ranges</measure>
    <time_frame>at least two days after thromboprophylaxis initiation</time_frame>
    <description>Proportion of patients whose peak plasma anti-Xa levels is in the prophylactic ranges.The target range for prophylactic anti-Xa levels is defined as 0.2 to 0.5 IU/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic VTE</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients with symptomatic VTE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with major bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>Proportion of patients with major bleeding</description>
  </secondary_outcome>
  <enrollment type="Actual">118</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Obese patients undergoing bariatric surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18 and 70 years old

          -  BMI ≥ 40 Kg/m² or BMI ≥ 35 Kg/m² with at least one or more obesity-related
             co-morbidities ( including type II diabetes (T2DM), hypertension, obstructive sleep
             apnea (OSA), non-alcoholic fatty liver disease, severe osteoarthritis, lipid
             abnormalities, gastrointestinal disorders, or heart disease)

          -  scheduled for sleeve gastrectomy (SG) or gastric bypass procedure (GBP)

          -  informed consent

        Exclusion Criteria:

          -  anticoagulant administration within 48 hours preceding surgery

          -  on-going antiplatelet therapy

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedicte Gaborit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inserm U1062, Inra U1260, Aix Marseille Université, Faculté de Médecine, Assistance Publique - Hôpitaux de Marseille</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Heparin, Low-Molecular-Weight</keyword>
  <keyword>Body Composition</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Bariatric Surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

